Introduction
Leading global pharmaceutical company launched the world’s first nebulized fixed-dose triple therapy for COPD, combining Glycopyrronium, Formoterol, and Budesonide to improve lung function and simplify patient treatment.
Also Read: HUDCO: Stock gains after signing MoU with IDFC for capacity development
Share price movement of Glenmark
On November 25, 2025, Glenmark Pharmaceuticals Ltd opened at ₹1,830.25, down 0.58% from its previous close of ₹1,841.05. The stock reached a high of ₹1,893.85 (2.82%) and a low of ₹1,830.25 (-0.58%). By 10:42 AM, it traded at ₹1,870.30, a 1.59% increase, with a market cap of ₹52,780.02 crore.
Glenmark Launches World’s First COPD Therapy
Glenmark Pharmaceuticals Ltd announced the launch of Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, the world’s first nebulized fixed-dose triple therapy for COPD patients in India.
The therapy combines Glycopyrronium, Formoterol, and Budesonide to reduce airway obstruction, inflammation, and improve lung function. It provides a single nebulized treatment, minimizing the need for multiple medications.
Clinical studies in India showed rapid improvement in lung function and better control of breathlessness. The treatment was well tolerated and demonstrated a good safety profile for COPD management.
Stock performance of Glenmark for Period of 1 week, 6 months, and 1 year
Glenmark Pharmaceuticals Ltd delivered a -0.02% return over the past week, gained 31.0% in the past six months, and increased 23.6% over the past year.
Also Read: B.R.Goyal Infrastructure: Stock jumps after ₹33.27 Cr NHAI contract for toll collection
Shareholding pattern of Glenmark
| Particulars | Sep 2025 | Jun 2025 | Mar 2025 |
| Promoter | 46.70% | 47% | 47% |
| FII | 21% | 21% | 23.20% |
| DII | 18.70% | 17.70% | 14.60% |
| Public | 14.00% | 15.10% | 15.60% |
About Glenmark
Glenmark Pharmaceuticals Ltd (NSE: GLENMARK) is a global, research-led pharmaceutical company operating in branded, generics, and OTC segments, with 11 manufacturing facilities across 4 continents and a presence in over 80 countries.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
A: Glenmark Pharmaceuticals Ltd share price rose after launching Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, the world’s first nebulized triple therapy for COPD.
A: Glenmark Pharmaceuticals Ltd specializes in branded, generics, and OTC pharmaceuticals, focusing on respiratory, dermatology, and oncology therapies globally.
A: Glenmark Pharmaceuticals Ltd stock has a 52-week high of ₹2,286.15 and a 52-week low of ₹1,274.70.
